2009 HESI Annual Meeting

Presentations

HESI Assembly

Introduction to HESI Portfolio
Dr. James MacDonald, Schering-Plough Research Institute

Development and application of biomarkers of toxicity
Dr. Ernie Harpur, sanofi-aventis

Immunotoxicology
Dr. Raegan O’Lone, HESI

Integration of Biomonitoring Exposure Data into the Risk Assessment Process
Dr. Christina Cowan, The Procter & Gamble Company

Protein Allergenicity
Dr. Michael Holsapple, HESI

Risk Assessment Methodology
Dr. Michelle Embry, HESI

Biological Significance of DNA Adducts
Dr. Gary Williams, New York Medical College

Cardiovascular Pro-Arrhythmia Models
Ms. Syril Pettit, HESI

Nanomaterial Environmental, Health and Safety
Ms. Nancy Doerrer, HESI

PPAR Agonist Tumorigenicity
Dr. Samuel Cohen, University of Nebraska Medical Center

Relevance and Follow-up of Positive Results in In Vitro Genetic Toxicity Testing
Dr. Bhaskar Gollapudi, The Dow Chemical Company

Emerging Issues Session

New Topic Areas for Consideration By HESI Constituency

Proposal for Identification of Pharmaceuticals for Validation of ToxCast
Dr. Robert Kavlock, US Environmental Protection Agency

External Perspective on ToxCast
Dr. Robert Chapin, Pfizer, Inc.

Human iPS Cell Technology and Its Application to Toxicology Testing
Dr. Samuel Cohen, University of Nebraska Medical Center

Improving Exposure Science and Dose Metrics for Toxicity Testing, Screening, Prioritizing, and Risk Assessment
Dr. Elaine Cohen-Hubal, US Environmental Protection Agency
Dr. Tim Pastoor, Syngenta Crop Protection

Reports on Existing HESI Emerging Isssues Subcommittees

Introduction
Dr. Ruth Lightfoot-Dunn, Amgen Inc.

Risk Assessment for Sensitive Populations
Dr. Ron Hines, Medical College of Wisconsin

State of the Science: Evaluating Epigenetic Changes
Dr. Jay Goodman, Michigan State University

Emergence of Animal Alternative Needs in Environmental Risk Assessment
Dr. Scott Belanger, The Procter & Gamble Company

Methodology for Intermittent / Short-term Exposure to Carcinogens
Dr. Gary Williams, New York Medical College

State-Of-The-Science Within HESI Session

Project Committee on the Development of Methods for a Tiered Approach to Assess Bioaccumulation
Dr. Christina E. Cowan-Ellsberry, The Procter & Gamble Company

Developmental and Reproductive Toxicology Technical Committee
Dr. Robert E. Chapin, Pfizer, Inc.

Application of Genomics to Mechanism-based Risk Assessment Technical Committee
Dr. Jiri Aubrecht, Pfizer, Inc.
Dr. Richard S. Paules, NIEHS